Learn about our strategy. Read more. Find out more Partnering for success. Learn more. Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs.
Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology. Ipsen delivers strong sales momentum in the first nine months of and increases itsβ¦.
Our Integrated Annual Report is live! Ipsen focuses on three key therapeutic areas, leveraging all our resources to help patients with unmet medical needs. Ipsen has been working in oncology since , and now has a portfolio that includes treatments for neuroendocrine tumor NETs , and cancers of the kidney, liver, pancreas, thyroid, prostate and breast. Ninety-four percent of rare medical conditions still have no treatment.
We are committed to finding treatments for extremely rare bone diseases and disorders, growth disorders, rare cancers, rare liver disease and rare neurogenetic disorders. Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenerative neurological conditions.
Our commitment to improving the lives and medical outcomes of patients is the driving force behind every decision made at Ipsen. We believe in working with patients, for patients, listening to their needs and involving their insights in the entire. At Ipsen, our shared purpose drives us to create a healthier, more resilient future for people and the planet.
